Last updated on November 2019

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)


Brief description of study

Primary Objective:

To describe the long-term safety of dupilumab in treatment of patients with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).

Detailed Study Description

Duration per participant is until dupilumab approval for use in asthma and market availability to the patient, or a maximum of 144 weeks (ie, about 3 years) after the Start of Treatment (V1), whichever comes first.

Clinical Study Identifier: NCT03620747

Find a site near you

Start Over

Investigational site nb 840057

South Burlington, VT United States
  Connect »

Belgium

Belgium, Belgium
  Connect »

CANADA

Canada, Canada
  Connect »

FRANCE

France, France
  Connect »

GERMANY

Germany, Germany
  Connect »

ISRAEL

Israel, Israel
  Connect »

Japan

Japan, Japan
  Connect »

South Africa

South Africa, South Africa
  Connect »

Netherlands

Netherlands, Netherlands
  Connect »